2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges

Richard Mihigo, Claudia Vivas Torrealba, Kanokporn Coninx, Deo Nshimirimana, Marie Paule Kieny, Peter Carrasco, Lisa Hedman, Marc-Alain Widdowson

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Abstract

To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic.

Original languageEnglish
JournalJournal of Infectious Diseases
Volume206 Suppl 1
Pages (from-to)S22-8
ISSN0022-1899
DOIs
Publication statusPublished - 15-Dec-2012

Keywords

  • Adolescent
  • Africa/epidemiology
  • Child
  • Child, Preschool
  • Developing Countries
  • Drug-Related Side Effects and Adverse Reactions/epidemiology
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype/immunology
  • Influenza Vaccines/administration & dosage
  • Influenza, Human/prevention & control
  • Male
  • Pregnancy
  • Vaccination/methods
  • World Health Organization

Fingerprint

Dive into the research topics of '2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges'. Together they form a unique fingerprint.

Cite this